These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 27567629)

  • 21. Mortality in patients with rheumatoid arthritis-associated interstitial lung disease treated with an anti-tumor necrosis factor agent.
    Koo BS; Hong S; Kim YJ; Kim YG; Lee CK; Yoo B
    Korean J Intern Med; 2015 Jan; 30(1):104-9. PubMed ID: 25589842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Change in Gait Deviation Index after anti-tumour necrosis factor-α treatment in individuals with rheumatoid arthritis: a pilot study.
    Broström EW; Esbjörnsson AC; von Heideken J; Larsson P; Wretenberg P; Iversen M
    Scand J Rheumatol; 2013; 42(5):356-61. PubMed ID: 23581251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differing local and systemic inflammatory burden in polyarticular psoriatic arthritis and rheumatoid arthritis patients on anti-TNF treatment in clinical remission.
    Ramírez J; Inciarte-Mundo J; Cuervo A; Ruiz-Esquide V; Hernández MV; Sanmartí R; Cañete JD
    Clin Exp Rheumatol; 2017; 35(1):74-79. PubMed ID: 27749227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study.
    Finckh A; Dehler S; Gabay C;
    Ann Rheum Dis; 2009 Jan; 68(1):33-9. PubMed ID: 18230627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sleep disturbances and interleukin 6 receptor inhibition in rheumatoid arthritis.
    Fragiadaki K; Tektonidou MG; Konsta M; Chrousos GP; Sfikakis PP
    J Rheumatol; 2012 Jan; 39(1):60-2. PubMed ID: 22133618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of 24 months of anti-TNF therapy versus methotrexate on body weight in patients with rheumatoid arthritis: a prospective observational study.
    Sfriso P; Caso F; Filardo GS; Botsios C; Costa L; Scarpa R; Todesco S; Spinella P; Oliviero F; Punzi L
    Clin Rheumatol; 2016 Jun; 35(6):1615-8. PubMed ID: 27048267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EFFECT OF THERAPY WITH ANTI-TNF α DRUGS AND DMARD ON DISEASE ACTIVITY AND HEALTH RELATED QUALITY OF LIFE AMONG WOMEN WITH RHEUMATOID ARTHRITIS.
    Kopciuch D; Paczkowska A; Leszczynsk P; Michalak M; Nowakowskai E
    Acta Pol Pharm; 2016; 73(2):547-54. PubMed ID: 27180448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry.
    Harrold LR; Reed GW; Magner R; Shewade A; John A; Greenberg JD; Kremer JM
    Arthritis Res Ther; 2015 Sep; 17(1):256. PubMed ID: 26382589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hospitalizations of patients treated with anti-tumor necrosis factor-α agents -- a retrospective cohort analysis.
    Zisman D; Haddad A; Hashoul S; Laor A; Bitterman H; Rosner I; Eder L; Balbir-Gurman A; Mader R; Milman U
    J Rheumatol; 2013 Jan; 40(1):16-22. PubMed ID: 23070992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Delayed treatment with tumor necrosis factor inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs shows an excellent effect in patients with very early rheumatoid arthritis with poor prognosis factors.
    Kita J; Tamai M; Arima K; Nakashima Y; Suzuki T; Kawashiri SY; Okada A; Koga T; Yamasaki S; Nakamura H; Origuchi T; Aramaki T; Nakashima M; Fujikawa K; Tsukada T; Ida H; Aoyagi K; Uetani M; Eguchi K; Kawakami A
    Mod Rheumatol; 2012 Apr; 22(2):195-201. PubMed ID: 21898075
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-alpha blocking agents.
    Halvorsen EH; Haavardsholm EA; Pollmann S; Boonen A; van der Heijde D; Kvien TK; Molberg Ø
    Ann Rheum Dis; 2009 Feb; 68(2):249-52. PubMed ID: 18723564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extraarticular manifestations of rheumatoid arthritis develop in patients receiving anti-tumor necrosis factor-α treatment: a retrospective chart review from a UK center.
    Negoescu AF; Tennekone D; Soljak MA; Abraham SM
    J Rheumatol; 2014 Oct; 41(10):1944-7. PubMed ID: 25179847
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Power Doppler ultrasonographic monitoring of response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis.
    Naredo E; Möller I; Cruz A; Carmona L; Garrido J
    Arthritis Rheum; 2008 Aug; 58(8):2248-56. PubMed ID: 18668537
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of certolizumab pegol in rheumatoid arthritis: meeting rheumatologists' requirements in routine clinical practice.
    Punzi L; Lapadula G; Mathieu A
    BioDrugs; 2014 Apr; 28 Suppl 1():S25-37. PubMed ID: 24687236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fatigue, rheumatoid arthritis, and anti-tumor necrosis factor therapy: an investigation in 24,831 patients.
    Wolfe F; Michaud K
    J Rheumatol; 2004 Nov; 31(11):2115-20. PubMed ID: 15517621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia.
    Metsios GS; Stavropoulos-Kalinoglou A; Douglas KM; Koutedakis Y; Nevill AM; Panoulas VF; Kita M; Kitas GD
    Rheumatology (Oxford); 2007 Dec; 46(12):1824-7. PubMed ID: 18032540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor necrosis factor-α antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series study.
    Lin KM; Cheng TT; Lin JC; Chen CJ
    Clin Rheumatol; 2015 Jun; 34(6):1039-46. PubMed ID: 25939523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
    Dixon WG; Watson K; Lunt M; Hyrich KL; Silman AJ; Symmons DP;
    Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disease activity improvement in rheumatoid arthritis treated with tumor necrosis factor-α inhibitors correlates with increased soluble Fas levels.
    Romano E; Terenzi R; Manetti M; Peruzzi F; Fiori G; Nacci F; Bellando-Randone S; Matucci-Cerinic M; Guiducci S
    J Rheumatol; 2014 Oct; 41(10):1961-5. PubMed ID: 25179850
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis.
    Popa C; van den Hoogen FH; Radstake TR; Netea MG; Eijsbouts AE; den Heijer M; van der Meer JW; van Riel PL; Stalenhoef AF; Barrera P
    Ann Rheum Dis; 2007 Nov; 66(11):1503-7. PubMed ID: 17472994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.